Axis Shielda

	Contact
	Téléphone : Mail : Adresse : PO Box 206 Ulvenveien 87 0510 Oslo Norvège Web :

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Profil scientifique partiel

	Quelques documents de Axis Shielda
	Demonstration of the clinical utility of holotc as an early marker of vitamin b12 deficiency HOLOTC, EARLY B12 MA 2002 - 2006 Sujets : Biotechnology, Environmental Protection, Innovation, Technology Transfer, Medicine, Health, Waste Management, Life Sciences Type de contrat : Demonstration contracts Participants : AARHUS KOMMUNEHOSPITAL - AARHUS UNIVERSITY HOSPITAL DANMARK AARHUS KOMMUNEHOSPITAL - AARHUS UNIVERSITY HOSPITAL Education Noerreborgade 44 8000 DANMARK THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UNITED KINGDOM THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Education,Other UNIVERSITY OFFICES, WELLINGTON SQUARE OX1 2JD UNITED KINGDOM THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN HEREINAFTER TRINITY COLLEGE DUBLIN ÉIRE/IRELAND THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN HEREINAFTER TRINITY COLLEGE DUBLIN Education DEPARTMENT OF BIOCHEMISTRY@@@ College Green ÉIRE/IRELAND UNIVERSITY OF BERGEN NORGE UNIVERSITY OF BERGEN Education,Other PO Box 7800 MUSEPLASS, 1 5020 NORGE AXIS-SHIELD ASA NORGE AXIS-SHIELD ASA Industry PO Box 206 Ulvenveien 87 0510 NORGE AXIS SHIELDA Norway AXIS SHIELDA Industry PO Box 206 Ulvenveien 87 Norway Hide objective Vitamin B12 deficiency occurs in 10% of the elderly (10 million in EU) and is associated with psychiatric morbidity (dementia and depression), costing EU many billions of ecru/year. Treatment is inexpensive and effective but identification of those needing therapy is hampered by the poor diagnostic accuracy of conventional tests. A European company has developed an assay to measure holotranscobalamin (helot), a sensitive marker of early B12 deficiency. The aims of the project are to demonstrate the analytical performance of this assay in 4 countries; to show its superiority to conventional methods for assessment of vitamin B12 status; and to demonstrate its value in older patients with depression or dementia. Socio-economic benefits will be: identification and early treatment of persons with B12-related morbidity; improved health economy, and promotion of European industry in laboratory diagnostics. Source : cordis